Synergy between CD8 T Cells and Th1 or Th2 Polarised CD4 T Cells for Adoptive Immunotherapy of Brain Tumours

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hoepner, Sabine ^a,b   Loh, Jacelyn M S ^a,c   Riccadonna, Cristina ^a   Derouazi, Madiha ^a   Maroun, Céline Yacoub ^a   Dietrich, Pierre Yves ^a   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; HOMING RECEPTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOACCUMULATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HOMING; CELL INTERACTION; CELL SPECIFICITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; SURVIVAL TIME; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

ANIMALS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL POLARITY; CYTOKINES; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECEPTORS, LYMPHOCYTE HOMING; TH1 CELLS; TH2 CELLS;

EID: 84878121756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063933     Document Type: Article

References (53)

1. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
2. Restifo NP, Dudley ME, Rosenberg SA, (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
3. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557.
4. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924.
5. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, et al. (2012) Primary brain tumours in adults. Lancet 379: 1984-1996.
6. Maes W, Van Gool SW, (2011) Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 60: 153-160.
7. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, et al. (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17: 4296-4308.
8. Heimberger AB, Sampson JH, (2011) Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 13: 3-13.
9. Dietrich PY, Dutoit V, Tran Thang NN, Walker PR, (2010) T-cell immunotherapy for malignant glioma: toward a combined approach. Curr Opin Oncol 22: 604-610.
10. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-5525.
11. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, et al. (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11: 394-402.
12. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, et al. (2008) TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181: 6720-6729.
13. Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, et al. (2010) Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res 70: 4829-4839.
14. Sigmundsdottir H, Butcher EC, (2008) Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 9: 981-987.
15. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, et al. (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22: 175-184.
16. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, et al. (2006) Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66: 4478-4487.
17. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, et al. (2007) Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67: 6451-6458.
18. Ransohoff RM, Engelhardt B, (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12: 623-635.
19. Zhu J, Yamane H, Paul WE, (2010) Differentiation of effector CD4 T cell populations. Annu Rev Immunol 28: 445-489.
20. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, et al. (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190: 617-627.
21. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, et al. (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197: 387-393.
22. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798.
23. Becher B, Segal BM, (2011) TH17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 23: 707-712.
24. Bromley SK, Mempel TR, Luster AD, (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9: 970-980.
25. Syrbe U, Siveke J, Hamann A, (1999) Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 21: 263-285.
26. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, et al. (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108: 1331-1339.
27. Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, et al. (2009) IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother 32: 793-802.
28. Wang LX, Shu S, Disis ML, Plautz GE, (2007) Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109: 4865-4876.
29. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347.
30. Hickey WF, (1999) Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 11: 125-137.
31. Wong SB, Bos R, Sherman LA, (2008) Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180: 3122-3131.
32. Bos R, Sherman LA, (2010) CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70: 8368-8377.
33. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, et al. (2007) Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 179: 845-853.
34. Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, et al. (2000) TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 123: 2005-2019.
35. Plautz G, Shu S, (1997) Adoptive immunotherapy of intracranial tumors by systemic transfer of tumor-draining lymph node cells (Review). Int J Oncol 11: 389-395.
36. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD, (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20: 267-275.
37. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. (2011) Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 29: 330-336.
38. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, et al. (2012) Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135: 1042-1054.
39. Martorelli D, Muraro E, Merlo A, Turrini R, Fae DA, et al. (2012) Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. Clin Dev Immunol 2012: 931-952.
40. Sallusto F, Lanzavecchia A, Mackay CR, (1998) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 19: 568-574.
41. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, et al. (2009) Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 69: 1587-1595.
42. Abastado JP, (2012) The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 72: 2159-2161.
43. Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, et al. (2003) Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 171: 2187-2191.
44. Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, et al. (2009) Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. J Immunol 183: 1828-1837.
45. Riccadonna C, Walker PR (2012) Macrophages and Microglia in Brain Malignancies. In: Biswas SK, editor. Tumor microenvironment and myelomonocytic cells. Rijeka: Intech. 173-200.
46. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, et al. (2006) The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8: 261-279.
47. Wu A, Wei J, Kong L-Y, Wang Y, Priebe W, et al. (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology 12: 1113-1125.
48. Wright JL, Merchant RE, (1997) Effects of an intratumoral injection of human recombinant tumor necrosis factor-alpha on cerebrovascular permeability and leukocytic infiltration in a rat glioma model. Acta Neuropathol 93: 78-86.
49. Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, et al. (2000) Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 123: 687-697.
50. Tepper RI, Pattengale PK, Leder P, (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512.
51. Hegazy AN, Peine M, Helmstetter C, Panse I, Fröhlich A, et al. (2010) Interferons Direct Th2 Cell Reprogramming to Generate a Stable GATA-3+T-bet+ Cell Subset with Combined Th2 and Th1 Cell Functions. Immunity 32: 116-128.
52. Muranski P, Restifo NP, (2009) Adoptive immunotherapy of cancer using CD4+ T cells. Curr Opin Immunol 21: 200-208.
53. Slingluff CL Jr, (2011) The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination? The Cancer Journal 17: 343-350.